Logo

BRTX

BioRestorative Therapies, Inc.

BRTX

BioRestorative Therapies, Inc. • NASDAQ
$1.08 ▼ -1.94% (-0.02)
Market Cap $9.19 M
52w High $2.55
52w Low $1.00
Dividend Yield 0%
P/E -0.74
Volume 12.19K
Outstanding Shares 8.52M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $11.8K ▼ $3.658M ▲ $-3.038M ▼ -25.748K% ▼ $-0.33 ▼ $-2.986M ▼
Q2-2025 $303.3K ▲ $3.6M ▼ $-2.656M ▲ -875.787% ▲ $-0.3 ▲ $-2.604M ▲
Q1-2025 $25K ▼ $4.83M ▲ $-5.34M ▼ -21.359K% ▼ $-0.64 ▼ $-4.756M ▼
Q4-2024 $43.3K ▼ $2.73M ▲ $-1.636M ▼ -3.779K% ▼ $-0.21 ▼ $-2.64M ▼
Q3-2024 $233.6K $2.502M $-1.091M -467.216% $-0.13 $-2.239M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.49M ▼ $5.643M ▼ $3.436M ▼ $2.207M ▼
Q2-2025 $7.381M ▼ $8.517M ▼ $3.671M ▼ $4.845M ▼
Q1-2025 $9.113M ▼ $10.327M ▼ $4.182M ▲ $6.145M ▼
Q4-2024 $10.733M ▼ $12.28M ▼ $3.748M ▼ $8.531M ▼
Q3-2024 $13.088M $14.573M $4.582M $9.992M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.038M ▼ $-2.901M ▼ $1.998M ▼ $-49.308K ▼ $-952.807K ▼ $-2.901M ▼
Q2-2025 $-2.656M ▲ $-2.694M ▲ $2.132M ▼ $888.138K ▼ $326.462K ▼ $-2.694M ▲
Q1-2025 $-5.34M ▼ $-2.779M ▼ $2.367M ▲ $1.093M ▲ $680.899K ▲ $-2.815M ▼
Q4-2024 $-1.636M ▼ $-2.348M ▼ $1.533M ▲ $-126.316K ▼ $-941.554K ▼ $-2.36M ▼
Q3-2024 $-1.091M $-1.7M $936.753K $0 $-762.803K $-1.758M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Royalty
Royalty
 $0 ▲$0 ▲$0 ▲$0 ▲
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement BioRestorative is still a pure development-stage biotech: it has essentially no revenue and has been reporting steady losses each year. The absolute size of the losses looks relatively small in corporate terms, but given how tiny the company is, they are still meaningful. Earnings per share look extremely negative mainly because of repeated reverse stock splits rather than suddenly exploding costs. Overall, the income statement tells the story of a company that spends on R&D and operations without yet having commercial products to bring money in.

Balance Sheet

Balance Sheet The balance sheet is very small and quite lean. The company has limited total assets and only a modest equity base, with no meaningful debt showing up. Cash levels have come down from earlier years, which suggests that the financial cushion is thin and will likely need to be replenished through future fundraising. The lack of debt reduces interest burden, but the small size of the balance sheet highlights financial vulnerability and dependence on capital markets or partners to fund ongoing work.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting the company’s spending on research, clinical work, and overhead without any offsetting revenue streams. There is essentially no spending on long-term physical assets, so the cash burn is mostly operating in nature. Free cash flow is negative and closely tracks operating cash flow, which means the business consumes cash and will likely require periodic capital raises to keep clinical and development programs moving forward.

Competitive Edge

Competitive Edge From a business standpoint, BioRestorative operates in a highly competitive and high-risk part of biotech, but it is targeting specific niches—chronic disc-related back pain and metabolic disorders—where current treatments are often unsatisfying. Its potential strengths are proprietary cell-processing methods, patent protection around both BRTX‑100 and ThermoStem, in‑house manufacturing capabilities, and an FDA Fast Track designation for its lead program. On the other hand, it competes against much larger companies and other cell‑therapy players, while still being at an early clinical stage with no approved products yet. Regulatory, clinical, and funding risks all weigh heavily on its competitive position.

Innovation and R&D

Innovation and R&D Innovation is the core of the company’s story. BRTX‑100 uses a patient’s own stem cells prepared under low‑oxygen conditions to better match the harsh environment of damaged spinal discs, aiming to actually repair tissue rather than just mask pain. ThermoStem takes a different angle, using donor-derived brown fat–related cells to address obesity and type 2 diabetes, which, if successful, could become an off‑the‑shelf therapy. The company has built patent portfolios around both platforms and operates its own compliant manufacturing facility, which is significant for quality control and scaling. However, most of this value is still theoretical: key programs are in mid‑stage or preclinical development, so clinical results over the next few years will largely determine whether this R&D effort translates into real-world treatments.

Summary

BioRestorative is an extremely early-stage, high‑risk biotech story built around regenerative cell therapies for back pain and metabolic disease. Financially, it has no ongoing revenue, a small and shrinking cash base, recurring operating losses, and a history of large reverse stock splits—signs of a company that relies on external funding and has experienced substantial shareholder dilution. Strategically, it has some notable assets: proprietary technology, growing intellectual property, FDA Fast Track status for its lead candidate, and its own manufacturing capability. The key uncertainties are whether clinical trials will confirm the promise of its science and whether it can consistently secure the funding needed to reach commercialization in such a competitive and capital‑intensive space.

NEWS

November 17, 2025 · 7:00 AM UTC

BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease

Read more

November 5, 2025 · 4:30 PM UTC

BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Read more

October 27, 2025 · 7:30 AM UTC

BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market

Read more

October 22, 2025 · 9:35 AM UTC

BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

Read more

October 15, 2025 · 9:35 AM UTC

BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit

Read more